参考文献: 1. Rosario, M. et al., 2015.DOP040 Relationship between vedolizumab pharmaco-kinetics and endoscopic outcomes in patients with Ulcerative Colitis. JCrohn'sColitis,9(S1), p.S1: S46. 2. Roblin, X. et al., 2016. DOP070 The relationship between vedolizumab drug con-centrations at or before week 6 and remission at week 14 in ulcerative colitis pati-ents from GEMINI 1.JCrohn's Colitis,10(S1), pp.S72-73. 3. Gils, A. et al., 2016.Abstract PO05:Variability in Vedolizumab Exposure between Patients with Inflammatory Bowel Disease.J Crohn's Colitis, 10(S1), p.S91. 4. Christ, C. et al.,2015.Development and validation of a Liquid Chromatographic Tandem Mass Spectrometric ( LC-MS / MS ) Assay for the Measurement of Vedo-lizumab (VLZ ) Levels in Patient Serum.JCrohn's Colitis,10(S1), pp.S380-381.